Successful desensitization to natalizumab using a 1-solution protocol

Natalizumab is a humanized IgG4 monoclonal antibody against the α4-subunit of integrin α4β1 (VLA4 [very late antigen 4]), which is expressed on activated T cells. Antagonism of this target is thought to interfere with leukocyte adhesion to the vascular wall, thereby interfering with leukocyte trafficking across the blood brain barrier and reducing the inflammation within the central nervous system. Natalizumab is indicated for the treatment of relapsing-remitting multiple sclerosis.

http://ift.tt/2fU4AMM